TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06979362: Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Preserved Ejection Fraction and Left Ventricu

Sponsor: Novo Nordisk A/S · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 200 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$398,400

Rescue Site Savings

+$265,600

Unlock Full NCT06979362 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06979362 Rescue Dossier →